Menu

Deep Tech Investment Announcement: Unlearn.AI

Learn how our second Deep Tech Fund investment accelerates clinical trials by using artificial intelligence

Written by

Alumni Ventures

Published on

Read

2 min

We’re pleased to announce that our Deep Tech Fund has made a second investment: Unlearn.AI.

AVG’s Deep Tech Fund invests in ventures that are focusing on valuable deep tech solutions. Likely target sectors include AI/machine learning, blockchain/distributed ledger, robotics, VR/AR/MR, genomics, advanced materials, longevity, and others.

Virtual Twins for Clinical Trials

Unlearn.AI develops machine learning platforms to create biological digital twins for the healthcare and pharmaceutical industries. These digital twins combine physical, physiological, and genetic information with machine learning models to create a virtual representation of an individual. The twins are used in clinical trials to augment and — perhaps, in the future, replace — control groups, especially in instances when not enough patients can be recruited.

Unlearn sets itself apart by using digital twins in clinical trials for non-oncological chronic diseases, carving out a distinct niche with few competitors, if any. Initially, they are targeting Alzheimer’s Disease and Multiple Sclerosis. Their pipeline includes Amyotrophic Lateral Sclerosis, Type 1 Diabetes, Huntington’s Disease, Parkinson’s Disease, Rheumatoid Arthritis, and Inflammatory Bowel Disease.

The Unlearn.AI Team and Deal

Unlearn’s Series A was led by 8VC, a fresh check. The firm invests in sectors where data is transformational to the enterprise and computation and AI can make a meaningful impact. Previous investors DCVC and Mubadala Ventures also participated, investing their full pro-rata allocations. Castor Ventures (AVG’s fund for MIT alums and friends) led the deal for AVG. Unlearn’s CEO and Co-Founder Charles Fisher is a post-doc MIT graduate.

What We Liked About the Deal

  • Market opportunity. Given that 20% of clinical trials fail because researchers can’t recruit enough patients, particularly in the control group, Unlearn has a clear value proposition and market opportunity.
  • Validated technology. Unlearn’s platform has been validated with an Alzheimer’s case study, and they are in the process of signing a contract for a Phase III Alzheimer’s study.
  • Competitive advantage. Unlearn has established a unique space for itself by using digital twins in non-oncological clinical trials. Most companies using digital twins operate in the oncology space, though not in clinical trials per se. Competitors who act as external control arms for clinical trials mainly use human patients.
  • Expanding use cases. Unlearn’s platform can be used beyond clinical trials for predictive, preventative, and personalized medicine.

AVG’s Deep Tech Fund invests in a venture portfolio of ~20-30 diverse companies tackling the toughest and potentially most lucrative tech challenges. The events of 2020 have underscored the critical importance of committing to and investing in science and rational thought for the well-being of society and the planet.

Get the Details » 

Contact [email protected] for additional information. To see additional risk factors and investment considerations, visit avg-funds.com/Disclosures.

Written by

Alumni Ventures

Alumni Ventures is a network-powered VC firm that helps accredited individuals invest in venture capital.

LinkedIn
Twitter
Facebook
Tagged with

Follow us

AVG Headquarters
670 N. Commercial Street
Suite 403
Manchester, NH 03101
General inquiries: [email protected]

Press inquiries: [email protected]

603-206-5508

Follow us

Neither Alumni Ventures Group nor any of its funds are sponsored by, affiliated with, or otherwise endorsed by any university. For further details see our Legal & Privacy Policy.

Video Policy: By consuming this content I acknowledge that I may be considering an investment with AV funds for my own or my client’s account. I agree that information contained herein may not be relied upon or used for any other purpose. Offers to purchase securities are only made through formal offering documents, which describe risks (which are significant), terms, and other important information that must be considered before an investment decision is made.

Testimonial Policy: Testimonials were provided by the participants without compensation, but each participant has a relationship with Alumni Ventures (AV) from which they benefit. All views expressed are the individual’s own and do not represent the experience of all AV fund investors or companies in which AV funds invest.

Investor Updates: Private investor portals and dashboards are updated once per quarter.

Alumni Ventures is America’s largest venture firm for individuals by combination of number of investors, investments and capital raised.

(1) Internal Rate of Return (IRR) for AV Funds is net of management fees and incentive allocations applied to amounts distributed to investors, and gross of incentive allocations applicable to unrealized gains on investments held by AV Funds. IRR for AV Funds includes uninvested cash, unrealized investments, and amounts distributed to investors. The IRR shown for the Russell 2000 indices are gross of fees because indices are not managed investments, and it is not possible to invest directly in an index. For additional information see av-funds.com/disclosures. All investment involves risk, including risk of loss. Past performance is not necessarily indicative of future results. For more information on AV Funds’ investment returns, please see here.

© 2024, Alumni Ventures Group. All rights reserved.